The study showed that compared with the mice in the negative control group, the mice in the combined anti-LAG-3 (beginning on the 10th day after tumor implantation) and anti-PD-1 therapy group achieved a moderate survival benefit, while the mice in the combined anti-LAG-3 (beginning on the 7th day after tumor implantation) and anti-PD-1 therapy group achieved a significant survival benefit, indicating that anti-LAG-3 therapy can kill tumor cells more effectively in the early stage of tumorigenesis than in a later stage. This evidence concerns the gene LAG3 and neoplasm.